Calithera Biosciences Inc to Acquire Assets From Takeda Pharmaceutical Co Ltd Call Transcript

Oct 18, 2021 / 09:30PM GMT
Operator

Ladies and gentlemen, thank you standing by, and welcome to the Calithera's business update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded. I would now like to turn the conference to your host, Stephanie Wong, CFO. Ma'am, you may begin.

Stephanie Wong - Calithera Biosciences, Inc. - CFO & Secretary

Thank you, operator, and good afternoon, everyone. Welcome to our conference call to discuss our agreement with Takeda Pharmaceuticals to acquire 2 clinical-stage assets, sapanisertib and mivavotinib. Joining me today are Susan Molineaux, Founder, President and CEO; and Keith Orford, Chief Medical Officer. Earlier today, we issued a press release that included an overview of the transaction, which can be accessed through our website at calithera.com, alongside an updated corporate deck.

Before we begin, I would like to remind you that today's discussion will include statements about our future expectations, plans that constitute forward-looking statements for the purposes of the safe harbor provisions of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot